Page last updated: 2024-11-05

systhane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

systhane: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)hexanenitrile : A nitrile that is hexanenitrile substituted at the 2-position by p-chlorophenyl and (1,2,4-triazol-1-yl)methyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6336
CHEMBL ID1904430
CHEBI ID83729
SCHEMBL ID21809
MeSH IDM0414396

Synonyms (76)

Synonym
AC-12516
c15h17cln4
NCGC00163776-03
NCGC00163776-02
NCGC00163776-01
nova (pesticide)
hsdb 6708
rh 3866
nu-flow m
synthane 12e
2-p-chlorophenyl-2-(1h-1,2,4-triazol-1-ylmethyl)hexanenitrile
hoe 39304f
1h-1,2,4-triazole-1-propanenitrile, alpha-butyl-alpha-(4-chlorophenyl)-
(+-)-myclobutanil
rally
caswell no. 723k
systhane 6 flo
nova w
myclobutanil [ansi:bsi:iso]
alpha-butyl-alpha-(4-chlorophenyl)-1h-1,2,4-triazole-1-propanenitrile
epa pesticide chemical code 128857
systhane
2-(4-chlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)hexanenitrile
myclobutanil ,
88671-89-0
NCGC00163776-04
(r)-2-p-chlorophenyl-2-(1h-1,2,4-triazol-1-ylmethyl)hexanenitrile
HMS2090D09
2-(4-chlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)hexanenitrile
A842831
NCGC00163776-07
NCGC00163776-05
NCGC00163776-06
C18477
NCGC00255034-01
dtxsid8024315 ,
tox21_301135
dtxcid304315
cas-88671-89-0
NCGC00259464-01
tox21_201915
unii-b6t1jtm6kz
b6t1jtm6kz ,
FT-0629047
nova
AKOS015895793
myclobutanil [mi]
1h-1,2,4-triazole-1-propanenitrile, .alpha.-butyl-.alpha.-(4- chlorophenyl)-
2-(4-chlorophenyl)-2-(1h-1,2,4-triazol-1- ylmethyl)hexanenitrile
2-p-chlorophenyl-2-(1h-1,2,4-triazol-1- ylmethyl)hexanenitrile
(+/-)-myclobutanil [hsdb]
myclobutanil [iso]
.alpha.-butyl-.alpha.-(4-chlorophenyl)-1h-1,2,4-triazole-1- propanenitrile
S5704
DL-452
2-((1h-1,2,4-triazol-1-yl)methyl)-2-(4-chlorophenyl)hexanenitrile
SCHEMBL21809
chebi:83729 ,
CHEMBL1904430
alpha-n-butyl-alpha-(4-chlorophenyl)-1h-1,2,4-triazole-1-propanenitrile
alpha-n-butyl-alpha(4-chlorophenyl)-1h-1,2,4-triazole-1-propanenitrile
AB01275509-01
.alpha.-butyl-.alpha.-(4-chlorophenyl)-1h-1,2,4-triazole-1-propanenitrile
rh-3866
CS-8015
HY-B2148
myclobutanil, pestanal(r), analytical standard
sr-05000001515
SR-05000001515-1
myclobutanil 10 microg/ml in cyclohexane
DS-3477
BCP21409
Q413587
AMY22474
CCG-267365
C76963

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Triazole fungicides associated with a range of reported male reproductive effects in experimental animals were selected to assess potential toxic modes of action."( Disruption of testosterone homeostasis as a mode of action for the reproductive toxicity of triazole fungicides in the male rat.
Best, DS; Blystone, CR; Dix, DJ; Goetz, AK; Narotsky, MG; Nichols, HP; Ren, H; Rockett, JC; Schmid, JE; Strader, LF; Thillainadarajah, I; Wolf, DC, 2007
)
0.34
" The particular mode of toxic and tumorigenic action for these compounds is not known, however it has been proposed that triadimefon-induced rat thyroid tumors arise through the specific mechanism of increased TSH."( Toxicity profiles in rats treated with tumorigenic and nontumorigenic triazole conazole fungicides: Propiconazole, triadimefon, and myclobutanil.
Allen, JW; Delker, D; George, MH; Hester, SD; Jones, C; Leavitt, S; Moore, T; Nelson, G; Nesnow, S; Roop, BC; Sun, G; Thai, SF; Thibodeaux, J; Winkfield, E; Wolf, DC, 2006
)
0.33
" Here, the dissipation and residual levels of three fungicides (pyraclostrobin, myclobutanil, and difenoconazole) were studied for strawberry under greenhouse conditions using high-performance liquid chromatography (HPLC)-tandem mass spectrometry after Quick, Easy, Cheap, Effective, Rugged, and Safe extraction."( Degradation of three fungicides following application on strawberry and a risk assessment of their toxicity under greenhouse conditions.
Cang, T; Sun, C; Wang, Q; Wang, X; Wang, Z; Yu, R; Zhao, X, 2015
)
0.42
" The hepatotoxic compounds induced the expected zebrafish liver degeneration or changes in size, whereas saccharin did not have any phenotypic adverse effect."( Phenotypic and biomarker evaluation of zebrafish larvae as an alternative model to predict mammalian hepatotoxicity.
Berckmans, P; Covaci, A; Hollanders, K; Maho, W; Peers, B; Remy, S; Verstraelen, S; Witters, H, 2016
)
0.43
" The toxicities identified include adverse effects on liver and kidney and on the development of male reproductive organs."( Myclobutanil worsens nonalcoholic fatty liver disease: An in vitro study of toxicity and apoptosis on HepG2 cells.
de Novellis, F; Lamberti, M; Pirozzi, AVA; Schiraldi, C; Stellavato, A, 2016
)
0.43
" There are large amounts of toxicological data available regarding myclobutanil, but the adverse effects of myclobutanil on lizards has not been widely reported."( Tissue distribution and toxicity effects of myclobutanil enantiomers in lizards (Eremias argus).
Chen, L; Cheng, C; Di, S; Diao, J; Li, R; Tian, Z; Zhang, W; Zhou, Z, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
"To establish chemical extraction procedures for predicting bioavailability of butachlor and myclobutanil in soil, several solvent systems, including methanol, methanol-water (9:1), methanol-water (1:1), acetone-water (5:3), petroleum ether and water, were assessed for their feasibility in determining extractability of the target compounds from soil samples."( Bioavailability of butachlor and myclobutanil residues in soil to earthworms.
Fang, H; Li, SN; Tan, YJ; Wu, XM; Yu, JQ; Yu, YL, 2005
)
0.33
"A study was conducted to determine the adsorption/desorption of butachlor, myclobutanil and chlorpyrifos on five soils using a batch equilibration technique and to study the relationship between bioavailability to Allolobophora caliginosa and the adsorption/desorption of these three pesticides."( An exploration of the relationship between adsorption and bioavailability of pesticides in soil to earthworm.
Fang, H; Li, SN; Wu, XM; Yu, JQ; Yu, YL; Zhan, HY, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Rats were dosed with the conazoles at three dose levels by gavage for 14 days: myclobutanil (150, 75, and 10mgkg(-1) body weight day(-1); triadimefon (115, 50, and 10 mg kg(-1) body weight day-'), which included their maximum tolerated dose levels (MTD)."( Induction of cytochrome P450 enzymes in rat liver by two conazoles, myclobutanil and triadimefon.
Dix, DJ; Grindstaff, RD; Lambert, GR; Nesnow, S; Sun, G; Thai, SF; Tully, DB, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
triazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pregnane X receptorRattus norvegicus (Norway rat)Potency28.79680.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.64040.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency30.89560.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency30.89560.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency25.69560.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency56.78220.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency43.41130.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency45.82190.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency61.64480.000214.376460.0339AID720691
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency56.81450.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency36.71160.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency42.11390.000229.305416,493.5996AID1259244; AID1259248; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency50.11870.001019.414170.9645AID588536
aryl hydrocarbon receptorHomo sapiens (human)Potency56.23410.000723.06741,258.9301AID651777
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency4.34650.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency45.68400.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency35.74500.000323.4451159.6830AID743065
heat shock protein beta-1Homo sapiens (human)Potency54.73940.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.63790.000627.21521,122.0200AID651741
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency30.51330.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency0.65980.002319.595674.0614AID651631; AID651743
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency30.51330.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1111054Antifungal activity against Podosphaera aphanis isolate SOC in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111061Antifungal activity against Podosphaera aphanis isolate MAR in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111064Antifungal activity against Podosphaera aphanis isolate HOR in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111053Antifungal activity against Podosphaera aphanis isolate SOD in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111051Antifungal activity against Podosphaera aphanis isolate VIR in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111056Antifungal activity against Podosphaera aphanis isolate SAG in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111057Antifungal activity against Podosphaera aphanis isolate PES in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111052Antifungal activity against Podosphaera aphanis isolate SOU in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111065Antifungal activity against Podosphaera aphanis isolate GUI in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111063Antifungal activity against Podosphaera aphanis isolate LBP in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1104912Toxicity in Typhlodromips swirskii infested green bean leaves assessed as mortality at recommended rate at 48 hr by leaf dip method (Rvb = 10%)2011Pest management science, Jan, Volume: 67, Issue:1
Effect of reduced risk pesticides on greenhouse vegetable arthropod biological control agents.
AID1111070Antifungal activity against Podosphaera aphanis isolate BRE in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111068Antifungal activity against Podosphaera aphanis isolate DAR1 in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111058Antifungal activity against Podosphaera aphanis isolate PAJ in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111055Antifungal activity against Podosphaera aphanis isolate SIL in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111074Antifungal activity against Podosphaera aphanis isolate ABA in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111066Antifungal activity against Podosphaera aphanis isolate DOU in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111073Antifungal activity against Podosphaera aphanis isolate AVI in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111067Antifungal activity against Podosphaera aphanis isolate DAR18 in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111072Antifungal activity against Podosphaera aphanis isolate ART in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111062Antifungal activity against Podosphaera aphanis isolate LI1 in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1104913Toxicity in Typhlodromips swirskii infested green bean leaves assessed as mortality at 2 times recommended rate at 48 hr by leaf dip method (Rvb = 10%)2011Pest management science, Jan, Volume: 67, Issue:1
Effect of reduced risk pesticides on greenhouse vegetable arthropod biological control agents.
AID1111059Antifungal activity against Podosphaera aphanis isolate MEP in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111071Antifungal activity against Podosphaera aphanis isolate BRA in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111069Antifungal activity against Podosphaera aphanis isolate CAM in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1111060Antifungal activity against Podosphaera aphanis isolate MEG in Darselect leaf disks after 8 days2010Pest management science, Jan, Volume: 66, Issue:1
Sensitivity of Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-sensitivity.
AID1104911Toxicity in Eretmocerus eremicus infested green bean leaves assessed as mortality at recommended rate at 48 hr by leaf dip method (Rvb = 10%)2011Pest management science, Jan, Volume: 67, Issue:1
Effect of reduced risk pesticides on greenhouse vegetable arthropod biological control agents.
AID1104910Toxicity in Eretmocerus eremicus infested green bean leaves assessed as mortality at 2 times of recommended rate at 48 hr by leaf dip method (Rvb = 10%)2011Pest management science, Jan, Volume: 67, Issue:1
Effect of reduced risk pesticides on greenhouse vegetable arthropod biological control agents.
AID1104914Toxicity in Orius insidiosus infested green bean leaves assessed as mortality at 2 times recommended rate at 48 hr by leaf dip method (Rvb = 20%)2011Pest management science, Jan, Volume: 67, Issue:1
Effect of reduced risk pesticides on greenhouse vegetable arthropod biological control agents.
AID1104915Toxicity in Orius insidiosus infested green bean leaves assessed as mortality at recommended rate at 48 hr by leaf dip method (Rvb = 20%)2011Pest management science, Jan, Volume: 67, Issue:1
Effect of reduced risk pesticides on greenhouse vegetable arthropod biological control agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (90)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's23 (25.56)29.6817
2010's52 (57.78)24.3611
2020's15 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.57 (24.57)
Research Supply Index4.52 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index74.66 (26.88)
Search Engine Supply Index3.19 (0.95)

This Compound (34.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.20%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other89 (97.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]